Dynamics of IgG-avidity and antibody levels after Covid-19
• IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection.
Gespeichert in:
| Autor*in: |
Löfström, Emma [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management - Scheen, Marc ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:144 ; year:2021 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jcv.2021.104986 |
|---|
| Katalog-ID: |
ELV055667147 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV055667147 | ||
| 003 | DE-627 | ||
| 005 | 20230624222945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2021.104986 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica |
| 035 | |a (DE-627)ELV055667147 | ||
| 035 | |a (ELSEVIER)S1386-6532(21)00253-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Löfström, Emma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamics of IgG-avidity and antibody levels after Covid-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. | ||
| 700 | 1 | |a Eringfält, Anna |4 oth | |
| 700 | 1 | |a Kötz, Arne |4 oth | |
| 700 | 1 | |a Wickbom, Fredrik |4 oth | |
| 700 | 1 | |a Tham, Johan |4 oth | |
| 700 | 1 | |a Lingman, Markus |4 oth | |
| 700 | 1 | |a Nygren, Jens M. |4 oth | |
| 700 | 1 | |a Undén, Johan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Scheen, Marc ELSEVIER |t Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV007727844 |
| 773 | 1 | 8 | |g volume:144 |g year:2021 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcv.2021.104986 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |j Immunologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 144 |j 2021 |h 0 | ||
| author_variant |
e l el |
|---|---|
| matchkey_str |
lfstrmemmaeringfltannaktzarnewickbomfred:2021----:yaisfgaiiynatbdlvl |
| hierarchy_sort_str |
2021 |
| bklnumber |
44.45 |
| publishDate |
2021 |
| allfields |
10.1016/j.jcv.2021.104986 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica (DE-627)ELV055667147 (ELSEVIER)S1386-6532(21)00253-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Löfström, Emma verfasserin aut Dynamics of IgG-avidity and antibody levels after Covid-19 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. Eringfält, Anna oth Kötz, Arne oth Wickbom, Fredrik oth Tham, Johan oth Lingman, Markus oth Nygren, Jens M. oth Undén, Johan oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:144 year:2021 pages:0 https://doi.org/10.1016/j.jcv.2021.104986 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 144 2021 0 |
| spelling |
10.1016/j.jcv.2021.104986 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica (DE-627)ELV055667147 (ELSEVIER)S1386-6532(21)00253-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Löfström, Emma verfasserin aut Dynamics of IgG-avidity and antibody levels after Covid-19 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. Eringfält, Anna oth Kötz, Arne oth Wickbom, Fredrik oth Tham, Johan oth Lingman, Markus oth Nygren, Jens M. oth Undén, Johan oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:144 year:2021 pages:0 https://doi.org/10.1016/j.jcv.2021.104986 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 144 2021 0 |
| allfields_unstemmed |
10.1016/j.jcv.2021.104986 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica (DE-627)ELV055667147 (ELSEVIER)S1386-6532(21)00253-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Löfström, Emma verfasserin aut Dynamics of IgG-avidity and antibody levels after Covid-19 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. Eringfält, Anna oth Kötz, Arne oth Wickbom, Fredrik oth Tham, Johan oth Lingman, Markus oth Nygren, Jens M. oth Undén, Johan oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:144 year:2021 pages:0 https://doi.org/10.1016/j.jcv.2021.104986 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 144 2021 0 |
| allfieldsGer |
10.1016/j.jcv.2021.104986 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica (DE-627)ELV055667147 (ELSEVIER)S1386-6532(21)00253-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Löfström, Emma verfasserin aut Dynamics of IgG-avidity and antibody levels after Covid-19 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. Eringfält, Anna oth Kötz, Arne oth Wickbom, Fredrik oth Tham, Johan oth Lingman, Markus oth Nygren, Jens M. oth Undén, Johan oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:144 year:2021 pages:0 https://doi.org/10.1016/j.jcv.2021.104986 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 144 2021 0 |
| allfieldsSound |
10.1016/j.jcv.2021.104986 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica (DE-627)ELV055667147 (ELSEVIER)S1386-6532(21)00253-5 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Löfström, Emma verfasserin aut Dynamics of IgG-avidity and antibody levels after Covid-19 2021 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. Eringfält, Anna oth Kötz, Arne oth Wickbom, Fredrik oth Tham, Johan oth Lingman, Markus oth Nygren, Jens M. oth Undén, Johan oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:144 year:2021 pages:0 https://doi.org/10.1016/j.jcv.2021.104986 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 144 2021 0 |
| language |
English |
| source |
Enthalten in Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management Amsterdam [u.a.] volume:144 year:2021 pages:0 |
| sourceStr |
Enthalten in Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management Amsterdam [u.a.] volume:144 year:2021 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Immunologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| authorswithroles_txt_mv |
Löfström, Emma @@aut@@ Eringfält, Anna @@oth@@ Kötz, Arne @@oth@@ Wickbom, Fredrik @@oth@@ Tham, Johan @@oth@@ Lingman, Markus @@oth@@ Nygren, Jens M. @@oth@@ Undén, Johan @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV007727844 |
| dewey-sort |
3610 |
| id |
ELV055667147 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055667147</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624222945.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2021.104986</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055667147</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(21)00253-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Löfström, Emma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dynamics of IgG-avidity and antibody levels after Covid-19</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eringfält, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kötz, Arne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wickbom, Fredrik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tham, Johan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lingman, Markus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nygren, Jens M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Undén, Johan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Scheen, Marc ELSEVIER</subfield><subfield code="t">Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007727844</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:144</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcv.2021.104986</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">144</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Löfström, Emma |
| spellingShingle |
Löfström, Emma ddc 610 bkl 44.45 Dynamics of IgG-avidity and antibody levels after Covid-19 |
| authorStr |
Löfström, Emma |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007727844 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.45 bkl Dynamics of IgG-avidity and antibody levels after Covid-19 |
| topic |
ddc 610 bkl 44.45 |
| topic_unstemmed |
ddc 610 bkl 44.45 |
| topic_browse |
ddc 610 bkl 44.45 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a e ae a k ak f w fw j t jt m l ml j m n jm jmn j u ju |
| hierarchy_parent_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| hierarchy_parent_id |
ELV007727844 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007727844 |
| title |
Dynamics of IgG-avidity and antibody levels after Covid-19 |
| ctrlnum |
(DE-627)ELV055667147 (ELSEVIER)S1386-6532(21)00253-5 |
| title_full |
Dynamics of IgG-avidity and antibody levels after Covid-19 |
| author_sort |
Löfström, Emma |
| journal |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| journalStr |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Löfström, Emma |
| container_volume |
144 |
| class |
610 VZ 44.45 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Löfström, Emma |
| doi_str_mv |
10.1016/j.jcv.2021.104986 |
| dewey-full |
610 |
| title_sort |
dynamics of igg-avidity and antibody levels after covid-19 |
| title_auth |
Dynamics of IgG-avidity and antibody levels after Covid-19 |
| abstract |
• IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. |
| abstractGer |
• IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. |
| abstract_unstemmed |
• IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Dynamics of IgG-avidity and antibody levels after Covid-19 |
| url |
https://doi.org/10.1016/j.jcv.2021.104986 |
| remote_bool |
true |
| author2 |
Eringfält, Anna Kötz, Arne Wickbom, Fredrik Tham, Johan Lingman, Markus Nygren, Jens M. Undén, Johan |
| author2Str |
Eringfält, Anna Kötz, Arne Wickbom, Fredrik Tham, Johan Lingman, Markus Nygren, Jens M. Undén, Johan |
| ppnlink |
ELV007727844 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jcv.2021.104986 |
| up_date |
2024-07-06T18:10:56.152Z |
| _version_ |
1803854236776136704 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055667147</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624222945.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2021.104986</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001560.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055667147</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(21)00253-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Löfström, Emma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dynamics of IgG-avidity and antibody levels after Covid-19</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• IgG antibodies are detectable six months after Covid-19. • IgG antibodies avidity index increases after Covid-19. • Avidity index is not suitable to differentiate between acute and previous covid-19 infection.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eringfält, Anna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kötz, Arne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wickbom, Fredrik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tham, Johan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lingman, Markus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nygren, Jens M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Undén, Johan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Scheen, Marc ELSEVIER</subfield><subfield code="t">Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007727844</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:144</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcv.2021.104986</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">144</subfield><subfield code="j">2021</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.398164 |